MVX504: PCP Vaccine

MVX504 is MiniVax's lead product candidate. As a vaccine, MVX504 will used for the prevention of PCP in susceptible individuals who are not currently infected by the fungus. The market for this vaccine could potentially be huge with approximately 33 million people suffering from HIV/AIDS worldwide. In order to access this large market, MiniVax will have to take MVX504 through the IND (Investigational New Drug) route of the FDA approval process